These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30649998)

  • 1. Assessing the Clinical Impact of Risk Models for Opting Out of Treatment.
    Kerr KF; Brown MD; Marsh TL; Janes H
    Med Decis Making; 2019 Feb; 39(2):86-90. PubMed ID: 30649998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use.
    Kerr KF; Brown MD; Zhu K; Janes H
    J Clin Oncol; 2016 Jul; 34(21):2534-40. PubMed ID: 27247223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calibration of risk prediction models: impact on decision-analytic performance.
    Van Calster B; Vickers AJ
    Med Decis Making; 2015 Feb; 35(2):162-9. PubMed ID: 25155798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the weighted area under the net benefit curve for decision curve analysis.
    Talluri R; Shete S
    BMC Med Inform Decis Mak; 2016 Jul; 16():94. PubMed ID: 27431531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision curve analysis: a novel method for evaluating prediction models.
    Vickers AJ; Elkin EB
    Med Decis Making; 2006; 26(6):565-74. PubMed ID: 17099194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding decision curve analysis in clinical prediction model research.
    Zhao L; Leng Y; Hu Y; Xiao J; Li Q; Liu C; Mao Y
    Postgrad Med J; 2024 Jun; 100(1185):512-515. PubMed ID: 38453146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical inference for decision curve analysis, with applications to cataract diagnosis.
    Sande SZ; Li J; D'Agostino R; Yin Wong T; Cheng CY
    Stat Med; 2020 Sep; 39(22):2980-3002. PubMed ID: 32667093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk manager formula for success: Influencing decision making.
    Midgley M
    J Healthc Risk Manag; 2017 Oct; 37(2):4. PubMed ID: 29064149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From decision to shared-decision: Introducing patients' preferences into clinical decision analysis.
    Sacchi L; Rubrichi S; Rognoni C; Panzarasa S; Parimbelli E; Mazzanti A; Napolitano C; Priori SG; Quaglini S
    Artif Intell Med; 2015 Sep; 65(1):19-28. PubMed ID: 25455562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing.
    Holtgrave DR
    PLoS Med; 2007 Jun; 4(6):e194. PubMed ID: 17564488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic aspects of clinical decision making: applications of clinical decision analysis.
    Crane VS
    Am J Hosp Pharm; 1988 Mar; 45(3):548-53. PubMed ID: 3285672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Importance of Uncertainty and Opt-In v. Opt-Out: Best Practices for Decision Curve Analysis.
    Kerr KF; Marsh TL; Janes H
    Med Decis Making; 2019 Jul; 39(5):491-492. PubMed ID: 31104561
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
    Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
    Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Putting risk prediction in perspective: relative utility curves.
    Baker SG
    J Natl Cancer Inst; 2009 Nov; 101(22):1538-42. PubMed ID: 19843888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.
    Wen S; Zhang L; Yang B
    Value Health; 2014 Jul; 17(5):619-28. PubMed ID: 25128056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S.
    Owusu-Edusei K; Hoover KW; Gift TL
    Am J Prev Med; 2016 Aug; 51(2):216-224. PubMed ID: 26952078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives.
    Steyerberg EW; Vedder MM; Leening MJ; Postmus D; D'Agostino RB; Van Calster B; Pencina MJ
    Biom J; 2015 Jul; 57(4):556-70. PubMed ID: 25042996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.